USO DE ANTICONCEPCION ANTES Y DESPUES DEL ABORTO TERAPEUTICO





USO DE ANTICONCEPCION ANTES Y DESPUES DEL ABORTO TERAPEUTICO

(especial para SIIC © Derechos reservados)
En este estudio se compara el empleo de anticoncepción previa a un embarazo no planeado y posterior a un aborto terapéutico.
goodyear9.jpg Autor:
Goodyear-smith, Felicity
Columnista Experto de SIIC

Institución:
Department of General Practice and Primary Health Care Faculty of Medical and Health Sciences University of Auckland Auckland, New Zealand


Artículos publicados por Goodyear-smith, Felicity
Coautor
Bruce Arroll, MB ChB PhD FRNZCGP* 
Department of General Practice and Primary Health Care, University of Auckland*
Recepción del artículo
19 de Mayo, 2004
Primera edición
5 de Mayo, 2005
Segunda edición, ampliada y corregida
7 de Junio, 2021

Resumen
Se comparó el uso de anticonceptivos, antes y después de un aborto terapéutico, en 1995, 1999 y 2002 en una clínica de Nueva Zelanda, mediante una revisión de casos consecutivos, anónimos y retrospectivos, de mujeres que concurrieron para la terminación de su embarazo. En 1999 se halló que la interrupción de los anticonceptivos orales en respuesta a los temores surgidos de la publicidad respecto de su vinculación con el tromboembolismo venoso fue del 9.5%. Casi el 50% de las usuarias de píldoras combinadas informaron que su embarazo se había producido por la suspensión del tratamiento, derivada del temor causado por los medios al sugerir que esos productos conllevaban riesgos para la salud, especialmente de “trombosis”. Estas mujeres que suspendieron el tratamiento tenían significativamente menos factores de riesgo identificados de tromboembolismo venoso que las usuarias de píldoras que no lo habían interrumpido por ese motivo. Los datos de 2002 indicaron la significativa declinación del uso de anticonceptivos preconcepcionales y el aumento de la elección del condón luego de la terminación del embarazo. Esto fue así principalmente por el creciente número de mujeres asiáticas que solicitaban el aborto. En 2002, 97% de las mujeres asiáticas no utilizaron anticonceptivos o sólo utilizaron condones antes de la concepción, y 62% eligieron condones o abstinencia luego de la terminación del embarazo. Los anticonceptivos orales fueron utilizados significativamente menos por las mujeres asiáticas que por las europeas antes del aborto (2.2% contra 31%; p = 0.0002) y luego de éste (23.5% contra 46%; p = 0.00006). Otros grupos étnicos mostraron pequeños cambios respecto del uso de anticonceptivos a lo largo del período de estudio.

Palabras clave
Aborto terapéutico, agentes anticonceptivos, planificación familiar


Artículo completo

(castellano)
Extensión:  +/-10.29 páginas impresas en papel A4
Exclusivo para suscriptores/assinantes

Abstract
Contraceptive use pre- and post-therapeutic abortion in 1995, 1999 and 2002 in a New Zealand clinic has been compared using retrospective anonymous consecutive case review of women presenting for termination of pregnancy. In 1999 it was found that panic-stopping of oral contraceptives in response to publicity-mediated fears regarding venous thromboembolism was implicated in 9.5%. Nearly 50% of combined pill users claimed their pregnancy resulted from panic-stopping because of media-promoted fear of health risks, especially “clots”. Panic-stoppers had significantly lower identified risk factors for venous thromboembolism than pill users who had not panic-stopped. In 2002 data indicated significant decline in pre-conception contraceptive use and increase in post-termination condom choice. This is predominantly from increasing numbers of Asian women presenting for abortion. In 2002 97% of Asian women used no contraception or condoms only pre-conception and 62% chose condoms or abstinence post-termination. Oral contraceptives are used significantly less by Asian than European women both pre-termination (2.2% compare 31%; p = 0.0002) and post-termination (23.5% compare 46%; p = 0.00006) Other ethnic groups showed little change in contraceptive use over the study periods.

Key words
Therapeutic abortion, contraceptive agents, family planning


Full text
(english)
para suscriptores/ assinantes

Clasificación en siicsalud
Artículos originales > Expertos del Mundo >
página   www.siicsalud.com/des/expertocompleto.php/

Especialidades
Principal: Obstetricia y Ginecología
Relacionadas: Atención Primaria, Bioética, Medicina Familiar, Medicina Interna, Salud Pública



Comprar este artículo
Extensión: 10.29 páginas impresas en papel A4

file05.gif (1491 bytes) Artículos seleccionados para su compra



Enviar correspondencia a:
Goodyear-Smith, Felicity
Patrocinio y reconocimiento:
Agradecimiento: Al personal de la clínica por su ayuda en la recolección de datos.
Bibliografía del artículo
  1. Abortion Advisory Committee. Report of the Abortion Advisory Committee for 2001. Wellington: Department of Courts; 2001.
  2. Contraception, Sterilisation, and Abortion Act,. In: 112; 1977.
  3. Te Kete Ipurangi. National Certificate of Educational Acheivement: Internal assessment resource reference number: Health/1/5 - B version 3 “A sexuality issues magazine”. In: Ministry of Education; 2002.
  4. Goodyear-Smith F, Arroll B. The pill scare: publicising remote risks exposes women to other dangers. NZ Fam Phys 2000;27:33-38.
  5. Goodyear-Smith F, Arroll B. Termination of pregnancy following panic-stopping of oral contraceptives. Contraception 2002;66:163-167.
  6. Goodyear-Smith F, Arroll B. Contraception before and after termination of pregnancy: can we do it better 116 (1186): 1-9. N Z Med J 2003;116:1-9.
  7. Bloemenkamp K, Rosendaal F, Helmerhorst F, Buller H, et al. Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen. Lancet 1995;2346:1593-1596.
  8. Rawlins M. Combined oral contraceptives and thromboembolism. London: Committee on Safety of Medicines; 1995.
  9. Office for National Statistics. Legal Abortions, June Quarter 1996. London, UK: Office for National Statistics; 1997.
  10. Skjeldestad FE. Increased number of induced abortions in Norway after media coverage of adverse vascular events from the use of third-generation oral contraceptives. Contraception 1997;55:11-4.
  11. Ministry of Health. Press release re low dose contraceptives. Wellington; 1995.
  12. Spitzer WO, Lewis MA, Heinemann LA, Thorogood M, et al. Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study. Transnational Research Group on Oral Contraceptives and the Health of Young Women. BMJ 1996;312:83-8.
  13. World Health Organisation Collaborative Study of Cardiovascular Disease & Steroid Hormone Contraception. Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease. Lancet 1995;346:1582-1588.
  14. Jick H, Jick S, Gurewich V, Myers M, et al. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components. Lancet 1995;346:1589-1593.
  15. Aggett M. Anatomy of a decision - Pills under scrutiny. NZ Doc 1997:19-20.
  16. Ministry of Health. Deaths with third generation oral contraceptives. Wellington: Prescriber Update; 1998.
  17. Spitzer WO. The 1995 pill scare revisited: anatomy of a non-epidemic. Hum Reprod 1997;12:2347-57.
  18. Gerstman BB, Piper JM, Freiman JP, Tomita DK, et al. Oral contraceptive oestrogen and progestin potencies and the incidence of deep venous thromboembolism. Int J Epidemiol 1990;19:931-6.
  19. Stadel BV. Oral contraceptives and cardiovascular disease. N Engl J Med 1981;305:672-7.
  20. Jick SS, Myers MW, Jick H. Risk of idiopathic cerebral haemorrhage in women on oral contraceptives with differing progestagen components. Lancet 1999;354:302-3.
  21. Vasilakis C, Jick SS, Jick H. The risk of venous thromboembolism in users of postcoital contraceptive pills. Contraception 1999;59:79-83.
  22. Lewis MA, Spitzer WO, Heinemann LA, MacRae KD, et al. Third generation oral contraceptives and risk of myocardial infarction: an international case-control study. Transnational Research Group on Oral Contraceptives and the Health of Young Women. BMJ 1996;312:88-90.
  23. Lewis MA, Spitzer WO, Heinemann LA, MacRae KD, et al. Lowered risk of dying of heart attack with third generation pill may offset risk of dying of thromboembolism. BMJ 1997;315:679-80.
  24. Egermayer P, Town GI. Venous thromboembolism: common fallacies in assessment and management. New Ethicals J 1999;June:13-18.
  25. Beral V, Hermon C, Kay C, Hannaford P, et al. Mortality associated with oral contraceptive use: 25-year follow-up of cohort of 46,000 women from Royal College of General Practitioners’ oral contraception study. BMJ 1999;318:96-100.
  26. PHARMAC. Data on prescription numbers and ex-manufacturer cost of 2nd and 3rd generation oral contraceptives for each June financial year since 1993. Wellington: PHARMAC; 2002.
  27. Hewell SW, Andrews JL. Contraceptive use among female adolescents. Clinical Nursing Research. 1996;5:356-63.
  28. Wiebe ER, Sent L, Fong S, Chan J. Barriers to use of oral contraceptives in ethnic Chinese women presenting for abortion. Contraception. 2002;65:159-63.
  29. Skjeldestad FE. Using induced abortion to measure contraceptive efficacy. Family Planning Perspectives. 1995;27:71-3, 96.
  30. Shain RN. Abortion practices and attitudes in cross-cultural perspective. American Journal of Obstetrics & Gynecology. 1982;142:245-51.
  31. Luo L, Wu SZ, Chen XQ, Li MX, et al. Induced abortion among unmarried women in Sichuan province, China. Contraception. 1995;51:59-63.
  32. Abortion Advisory Committee. Report of the Abortion Advisory Committee for 1997. Wellington: Department of Courts; 1997.
  33. Abortion Advisory Committee. Report of the Abortion Advisory Committee for 2002. Wellington: Department of Courts; 2002.

 
 
 
 
 
 
 
 
 
 
 
 
Está expresamente prohibida la redistribución y la redifusión de todo o parte de los contenidos de la Sociedad Iberoamericana de Información Científica (SIIC) S.A. sin previo y expreso consentimiento de SIIC.
ua31618